Jenny Lowe
0000-0002-8565-2723
GlaxoSmithKline Plc
2 papers found
Refreshing results…
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
Missing publications? Search for publications with a matching author name.